Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
17 December 2010Website:
http://www.assemblybio.comNext earnings report:
28 March 2025Last dividends:
N/ANext dividends:
N/APrice
regular market | Tue, 19 Nov 2024 21:00:00 GMTDividend
Analysts recommendations
Institutional Ownership
ASMB Latest News
– Data from both ABI-5366 and ABI-1179, novel long-acting helicase-primase inhibitor candidates for recurrent genital herpes, to be presented –
– Phase 1a study portion of single ascending dosing in healthy participants will inform the development of ABI-5366 with interim data expected in Q3 2024 –
-- Preclinical data from both ABI-5366 and ABI-1179, Assembly Bio's long-acting helicase-primase inhibitor candidates targeting recurrent genital herpes, featured in poster and oral presentations at the International Herpesvirus Workshop -- -- Poster accepted for presentation at EASL Congress™ 2024 highlights preclinical profile of ABI-6250, a novel, small molecule orally-bioavailable entry inhibitor candidate for hepatitis D --
Penny stocks, defined as stocks trading under $5 per share, offer investors the allure of exponential growth. As an inherently volatile market sector, penny stocks can rapidly surge on positive news, rumors, and breakthroughs – allowing traders to potentially lock in short-term gains.
Assembly Biosciences (NASDAQ: ASMB ) stock is taking off on Tuesday after announcing a massive collaboration with Gilead Sciences (NASDAQ: GILD ). According to a press release, these two companies have entered into a 12-year partnership agreement.
What type of business is Assembly Biosciences?
Assembly Biosciences, Inc. operates as a clinical-stage biotechnology company in the United States. The company is developing oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and a new class of oral synthetic live biotherapeutic candidates for microbiome-related disorders. It is involved in the development of core inhibitors that suppress the functional activity of the HBV core protein at various stages of the virus life cycle. The company was previously known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in South San Francisco, California.
What sector is Assembly Biosciences in?
Assembly Biosciences is in the Healthcare sector
What industry is Assembly Biosciences in?
Assembly Biosciences is in the Biotechnology industry
What country is Assembly Biosciences from?
Assembly Biosciences is headquartered in United States
When did Assembly Biosciences go public?
Assembly Biosciences initial public offering (IPO) was on 17 December 2010
What is Assembly Biosciences website?
https://www.assemblybio.com
Is Assembly Biosciences in the S&P 500?
No, Assembly Biosciences is not included in the S&P 500 index
Is Assembly Biosciences in the NASDAQ 100?
No, Assembly Biosciences is not included in the NASDAQ 100 index
Is Assembly Biosciences in the Dow Jones?
No, Assembly Biosciences is not included in the Dow Jones index
When was Assembly Biosciences the previous earnings report?
No data
When does Assembly Biosciences earnings report?
The next expected earnings date for Assembly Biosciences is 28 March 2025